Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Landskrona – page 79

1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Landskrona at a glance
1 405
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 405 trials in Landskrona

Open in trial search

Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Casimersen
  • Sponsor:Sarepta Therapeutics Inc.

Study on Durvalumab and Stereotactic Body Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vastra Gotalandsregionen

Myasthenia gravis

Not recruiting

Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Study on the Safety of EDV2209 for Patients with Brain Bleeding (Subarachnoid Hemorrhage)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:EDV2209 hemiethanolate
  • Sponsor:Edvince AB

Thalassaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Non-Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Long-Term Safety and Effectiveness of Liposomal Ciclosporin A for Patients with Bronchiolitis Obliterans Syndrome After Lung Transplantation

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin A
  • Sponsor:Zambon S.p.A.

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Thalassaemia

Not recruiting

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Hypoparathyroidism

Not recruiting

Study on the Safety and Effectiveness of TransCon PTH for Adults with Hypoparathyroidism

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Palopegteriparatide
  • Sponsor:Ascendis Pharma Bone Diseases A/S

Study on Hydrocortisone and Placebo for Patients with Giant Cell Arteritis or Polymyalgia Rheumatica Experiencing Adrenal Insufficiency Symptoms

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Odense University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Landskrona

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.

  • Heart Failure Management
  • Cardiovascular Outcomes
  • Treatment Optimization

The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.

02 Urological Oncology

Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.

  • Bladder Cancer Treatment
  • Recurrence Prevention
  • Post-surgical Care

This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.